Life Science Investment Ltd
LSI in brief
LSI in brief

A passion for skin physiology

Founded in 1999 in London by Dr. Christian Diehl, LSI is a pharmaceutical company focused on the areas of dermatology, plastic surgery and aesthetic medicine.
We intend to develop cosmeceuticals and nutraceuticals oriented to the treatment and prevention of skin diseases and skin aging. Our goal is to offer healthcare professionals new, innovative, efficient and safe alternatives for prescriptions.

LSI, an active player in dermatology, plastic surgery and aesthetic medicine.
• An international presence in over 70 countries.
• 3 manufacturing sites (2 in Switzerland and 1 in Ecuador).
• 1 operational base in Switzerland.
• 5% of net sales dedicated to R&D.
• Founded in 1999 in London (UK).

Our commitment

For more than 15 years, LSI has been dedicated to develop and market innovative, efficient and safe products aimed at the improvement of various skin conditions.
Our goal is making these products accessible to an ever growing number of physicians around the world, for a better health and well-being of their patients.

Dr. Christian Diehl, a true skin passionate.

Dr. Christian Diehl is a pharmacologist who has always been passionate about skin physiology, and since 1980 he decided to focus on his passion. He created successively various successful companies, all of them in the same area, and besides was a consultant for various multinational pharmaceutical companies. Nowadays he is exclusively dedicating more than 35 years of professional expertise to LSI.

2007 Dr. Silvia Chami de Diehl becomes a Director of LSI.
Master in Nutrition (National University of Cordoba, Argentina), Researcher of natural active ingredients for the production of dermo-cosmetic products, Masters in Marketing (National University of Cordoba, Argentina).


2015 The world famous BIOTOPIX® line has a New Model image, and the new BIOTOPIX® website has been launched along with other social media sites.

2014 LSI’s logo has been redesigned depicting a new modern look of the traditional pantheon emblem.

2013 Launch of SODERMIX® Pills, an oral form of LSI’s proprietary ingredient EXTRASOD under the form of gastro-resistant tablets.

2012 Launch of the DERMANUTRIX® range, an original and complete line of nutraceuticals for a variety of dermatological disorders.

2011 LSI creates its own International Dermatology Research Center (CIFAC) in Guayaquil, Ecuador.

2011 Launch of POSTOPIX®, a cosmeceutical product aimed to alleviate and improve the appearance of post-procedure bruising.

2010 Launch of QUASIX®, a product range based on Quassia extract for the treatment and prevention of rosacea and seborrheic dermatitis.

2009 Launch of BIOTOPIX®, advanced anti-wrinkles treatment containing 4 active peptides.

2009 For its 10th anniversary, LSI has its products marketed in over 50 countries.

2007 Agreement with Italian pharmaceutical company SANITAS for the promotion and worldwide distribution of SINEDEC®, a medical device for the prevention and treatment of grade-I ulcers.

2007 Launch of SODERMIX® in its first indication: treatment and prevention of keloids and hypertrophic scars.

2006 Cessation of VITIX to ACM-Crawford.

2003 Development of SODERMIX®, the first topical form of Superoxide Dismutase (SOD).

2001 Launch of VITIX®, the first cosmeceutical aimed at the management of vitiligo.

1999 Creation of LSI.

Our history

Cosmeceuticals feature a new hot topic in the cosmetic and pharmaceutical industry, which is now the fastest-growing segment in these activities. The word cosmeceutical was forged 40 years ago by a great dermatologist Albert Kligman.


Cosmetic + Pharmaceutical = Cosmeceutical


A new category of products for dermatological use was born, intermediary between cosmetics and drugs for topical use.
Cosmeceuticals represent a necessity for the dermatologists, who are traditionally using for a long time some cosmetic products as complements for dermatologic treatments.

Following continuous advances in the knowledge of skin physiology and continuous occurrence of new active ingredients positively affecting skin functions and having a beneficial activity for the skin, cosmeceuticals were born.

In spite of a regulatory vacuum throughout the world, cosmeceuticals have been a reality and a necessity for both physicians and patients.

Cosmeceuticals are applied topically as cosmetics, but contain ingredients that influence the skin’s biological functions.

Cosmeceuticals are a fast-growing market, with an average growth of 10,1% per year between 2002 and 2007 and 7,4% between 2007 and 2012. The market size is actually ranging around 8,25 billion US$ (2012) and expected to be as high as 11,5 billion US$ in 2017.


Nutraceutical is a portmanteau of the words nutrition and pharmaceuticals corned by Dr. Stephen L. DeFelice.

The term is applied to products that range from isolated nutrients, dietary supplements, herbal products, and some processed foods.

As for cosmeceuticals, the term has generally no meaning in terms of regulation. In Canada it is defined as a “product isolated or purified from foods that is generally sold in medicinal forms not usually associated with food.
A nutraceutical is demonstrated to have a physiological benefit or provide protection against a chronic disease”.

The launch of targeted products scientifically formulated to address disease conditions is expected to support the growth of the nutraceutical market in the near future, which could be reaching a volume of US$ 250 billion by 2018.


At this time, LSI does not own its proper Manufacturing facilities but relies on three contract-manufacturing partners. This is a deliberate choice, in order to dedicate the best of our investments to our core business, R&D and marketing.

Meanwhile our manufacturing partners were carefully selected in order to ensure that physicians’ and customers’ needs are met using high service standards.

We currently possess three manufacturing sites.
The two cosmeceutical sites are located in Switzerland, in the Wallis region.

In Switzerland perfection is a second nature. Our partners’ permanent concern is maintaining constant quality to offer the best products with highest standards. Both have been implementing for a long time quality control processes to ensure the excellence of our products, under our strict and permanent supervision.

Both are in compliance with the ISO 22716 standards and have certification from SWISSMEDIC, the Swiss medical agency.

As regards to nutraceuticals, we entirely rely on Rocnarf Laboratories, a pharmaceutical company committed since 1976 to elaborating high-quality pharmaceutical products.

Further to applying international GMP standards, Rocnarf Labs. is proud to be certified ISO 9001-2008 by SGS.


As R&D and design of new, innovative products supported by strong clinical evidences is our major Concern, LSI has created in 2011 its own R&D center.

Named CIFAC (Research Center in Cutaneous Pharmacology, in Spanish) this center is based in Guayaquil, Ecuador.
Its geographical location, the biodiversity and natural as well as human resources of Ecuador give this country a high potential for being a strategic partner in the
development of new therapeutic alternatives.

Pre-clinical and clinical development take place in this center, where a staff of skilled professionals ( clinical trial manager, clinical trial monitors, statistician, data manager, scientific writer and dermatologists) work together supported by the most advanced technologies in bioengineering, following the strict guidelines of the Declaration of Helsinki and GCP.

CIFAC is certified ISO 9001 from its very creation.

Ethics and Values
Ethics and Values

Our ambition at LSI is to be recognized as a significant player in the world of dermatology and aesthetic medicine.

We commit to develop and promote innovative, efficient and safe alternative solutions for the physicians, for the benefit of their patients.

These products must be further manufactured following the strictest quality standards, and their distribution and promotion must be online with our ethical commitment.

Accurate information to the physicians prescribing our products is of utmost importance.

This is the way we can make our values a daily reality.
As our skin is our interface to the world, our passion is gaining meaning.

We consider our focus on the patients as the first of all values at LSI, and our duty is bringing them at any time the most innovative response they deserve for their problem.

Our focus

Keloids and hypertrophic scars

Both keloids and hypertrophic scars are a result of an overgrowth of granulation tissue at the site of a healed skin injury.
Keloids differ from hypertrophic scars in that they go beyond the limits of original lesion, while hypertrophic scars are limited to the lesional area.

Both of them are benign, but may be painful and itchy and affect movements when located over a joint. In any case they are unaesthetic and of serious concern for the affected patients.

Keloids and hypertrophic scars may develop at any age, but appear to be more frequent among individuals aged 20-40.
They are not frequent in children under 10 and in elder people.
They are much more frequent in Blacks than in Asians, than in Caucasians.
They affect both genders equally.

The best treatment is prevention in patients with known predisposition, including refraining from unnecessary surgeries and traumas (including ear piercing).
Intralesional injections of corticosteroids are often practiced, such as the use of silicon sheets or gel.

Our focus

Rosacea is a chronic skin condition featuring facial erythema (redness) which becomes permanent with the occurrence of telangiectasiae (small dilated blood vessels), papules and sometimes pustules (pimples).

Rosacea affects more likely females than males (80/20) and usually appears after the age of 20.
Rosacea has long been nicknamed “curse of the Celts” as it was thought to affect more likely fair-skinned individuals but this is more and more questioned, as it can occur in any racial group.

There are well-known triggering factors: sun exposure, heat, cold, sudden changes of temperature, spicy foods, alcohol intake, hot drinks such as coffee or tea and stress.

Rosacea typically begins as symmetrical redness on the central face across the cheeks, nose or forehead, but can also affect the chin. Rosacea is limited to the face and does not affect the body. Its exact cause is not completely understood.

Commensal Demodex mite was long considered as guilty of rosacea, but it appears more and more that this is not true, and that rosacea is mainly the consequence of oxidative stress (free radicals) at the skin level, which can be partly caused by Demodex, but also by all afore mentioned triggering factors.

Treatment of rosacea has long been based on the use of topical metronidazole, an anti-parasitic drug, and systemic treatment with antibiotics and/or metronidazole. The current trend is more and more oriented toward the use of topical antioxidants, and anti-inflammatories. Of course, rosacea patients must be careful and avoid all the triggering factors listed above.

Skin Aging

As skin ages it becomes thinner, less elastic and healing turns to be more difficult.
Fine lines and wrinkles progressively appear and age spots may also occur.
It must be distinguished between intrinsic aging and extrinsic aging.

Intrinsic aging is inevitable and only depends on the time. Of course each one has more or less predisposition to intrinsic aging, as genetic factors seem to play a large role at this stage.

On the contrary, much can be done to avoid or at least delay extrinsic aging, which is caused by various agents: first and most important sun exposure, but also smoking, alcohol intake, stress, environmental pollution and poor diet.

The molecular basis of skin aging are well-known to date: it is essentially the result of oxidative stress, i.e. the presence in the skin of abnormally high levels of free radicals in the skin.
When aging, our skin loses its ability of efficiently fighting against these free radicals, and oxidative damage occurs as a result.
Let’s keep in mind that skin starts aging as soon as the age of 20.

We must be careful, and besides the prevention from the agents susceptible of speeding up extrinsic skin aging, an adequate daily skin-care is compulsory, which can be supported by regular intake of oral antioxidants.

Our history
LSI in brief
Skin Nutraceuticals

Our skin is our interface to the world, but also a mirror of our internal health.

This is why nutraceuticals are taking an ever larger place in dermatologic prescription, as nutraceuticals support healthy skin function.

Cosmetics work only in surface, while nutraceuticals are providing essential nutrients to our skin, which can be lacking from our diet and are transported via the blood to the skin cells.

Nutraceuticals consisting of selected natural and active nutrients may be highly beneficial to the skin. Such nutrients nourish the cells at a deeper level, support the main metabolic functions and hence play an important role in the health and beauty of the face and body.

Creams work only on the top layer of the skin, while the dermis contains cells responsible for the synthesis of collagen, elastin, hyaluronic acid and other molecules which are essential for the hydration, elasticity, solidity, protection and restoration of our skin.

Life Science Investments Ltd. - Unit 3D, North Point House Business Park, New Mallow Road.
Cork T23AT2P, Ireland   |   © LSI 2019. All Rights Reserved